Galenica SA, seeking solutions that meet the current therapeutic needs of patients, invests in Know-How and promotes research collaborations aimed at the development of innovative pharmaceutical products and/or health care products.
The main research activity of the company takes place in a space of 300sqm equipped with modern R&D equipment (both productive and analytical), which aims at the development of new innovative pharmaceutical forms and products.
Galenica has already and established and successful cooperation with Greek Universities, such as the University of Athens, the University of Crete, the University of Patras and Ioannina and International, such as the University of Innsbruck, as well as other public research bodies (BRFAA) GALENICA has managed to acquire know-how in two promising subjects (oncology and pharmaceuticals of plant origin).
The R&D currently focuses on:
- Development of new products (new innovative formulations and / or new ways of administration).
- Research and development of new innovative medicines and nutritional supplements of plant origin utilizing the great biodiversity of Greek nature as well as the vast traditional medical knowledge in collaboration with Greek universities.
- Development of new innovative molecules in oncology targeting hormone-dependent tumors (ovarian cancer, prostate cancer, breast cancer).